Stock Scorecard

Stock Summary for Adial Pharmaceuticals Inc (ADIL) - $0.69 as of 5/5/2025 4:31:45 PM EST

Total Score

10 out of 30

Safety Score

24 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ADIL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ADIL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ADIL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ADIL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ADIL (24 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ADIL

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - Adial Pharmaceuticals ( NASDAQ:ADIL ) 5/2/2025 3:48:00 PM
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds 5/2/2025 3:48:00 PM
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Apple ( NASDAQ:AAPL ) , Adial Pharmaceuticals ( NASDAQ:ADIL ) 5/2/2025 9:02:00 AM
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - Adial Pharmaceuticals ( NASDAQ:ADIL ) 5/1/2025 12:02:00 PM
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update 3/4/2025 1:30:00 PM
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Adial Pharmaceuticals ( NASDAQ:ADIL ) 2/25/2025 1:30:00 PM
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies 2/19/2025 2:00:00 PM
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders 2/12/2025 2:00:00 PM
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Adial Pharmaceuticals ( NASDAQ:ADIL ) 2/12/2025 1:30:00 PM
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Adial Pharmaceuticals ( NASDAQ:ADIL ) 1/29/2025 1:31:00 PM

Financial Details for ADIL

Company Overview
Ticker ADIL
Company Name Adial Pharmaceuticals Inc
Country USA
Description Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/12/2025

Stock Price History
Last Day Price 0.69
Price 4 Years Ago 67.50
Last Day Price Updated 5/5/2025 4:31:45 PM EST
Last Day Volume 807,395
Average Daily Volume 1,096,985
52-Week High 1.68
52-Week Low 0.58
Last Price to 52 Week Low 18.97%

Valuation Measures
Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE -15.28
Free Cash Flow Ratio 1.21
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 4.16
Total Cash Per Share 0.57
Book Value Per Share Most Recent Quarter 0.63
Price to Book Ratio 1.08
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 6,574,600
Market Capitalization 4,536,474
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -88.48%
Reported EPS 12 Trailing Months -2.72
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.74
Net Income Twelve Trailing Months -13,197,451
Net Income Past Year -13,197,451
Net Income Prior Year -7,001,890
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 3,750,525
Total Cash Past Year 3,750,525
Total Cash Prior Year 2,827,082
Net Cash Position Most Recent Quarter 3,721,437
Net Cash Position Past Year 3,721,437
Long Term Debt Past Year 29,088
Long Term Debt Prior Year 29,088
Total Debt Most Recent Quarter 29,088
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 4,068,084
Total Stockholder Equity Prior Year 4,083,529
Total Stockholder Equity Most Recent Quarter 4,068,084

Free Cash Flow
Free Cash Flow Twelve Trailing Months -6,922,306
Free Cash Flow Per Share Twelve Trailing Months -1.05
Free Cash Flow Past Year -6,922,306
Free Cash Flow Prior Year -13,613,618

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.52
20-Day Bollinger Middle Band 0.80
20-Day Bollinger Upper Band 1.07
Beta 1.26
RSI 43.92
50-Day SMA 5.13
150-Day SMA 0.00
200-Day SMA 19.96

System
Modified 5/5/2025 4:31:47 PM EST